<DOC>
	<DOC>NCT00135967</DOC>
	<brief_summary>Patients with idiopathic membranous nephropathy and renal insufficiency are at risk for end-stage renal disease (ESRD). Treatment with cyclophosphamide is currently used as a treatment modality. Mycophenolate mofetil is a new immunosuppressive agent with fewer side effects. In this pilot study patients with membranous nephropathy and renal failure will be treated with mycophenolate mofetil and prednisone. The outcome will be compared with historical controls treated with a similar regimen containing cyclophosphamide.</brief_summary>
	<brief_title>Mycophenolate Mofetil in Membranous Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis, Membranous</mesh_term>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Membranous nephropathy Serum creatinine (Screat)&gt; 1,5 mg/dl or ECC &lt; 70 ml/min or increase Screat &gt; 50% Proteinuria &gt; 2 g/day Systemic diseases Pregnancy wish Active infection Liver dysfunction Abnormal hematology lab Unstable angina Nonsteroidal antiinflammatory agents (NSAIDs)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>membranous nephropathy</keyword>
	<keyword>mycophenolate mofetil</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>prednisone</keyword>
</DOC>